GLP-1 for Spinal Cord Injury Patients: Mobility-Limited Obesity

Roughly 300,000 US adults live with a spinal cord injury, and about 17,000 new cases are added every year. Among them, the prevalence of obesity is approximately 60% — far above the 42% general-population figure — driven by reduced resting energy expenditure, accelerated lean-mass loss, and impaired thermogenesis below the injury level (Gorgey 2007^[2], Nevin 2024^[3]). The first dedicated clinical-considerations paper on GLP-1 receptor agonists for this population (Farkas 2026, Archives of Physical Medicine and Rehabilitation^[1]) was published in early 2026. It frames GLP-1 therapy as potentially high-value in spinal cord injury but flags a unique cluster of risks: additive constipation on top of neurogenic bowel, hypotension on top of a chronically low baseline blood pressure, and pressure injuries in patients who lose the soft-tissue padding that protected bony prominences. This article walks through what the evidence actually says and the practical protocol it implies.

The honest summary

• SCI obesity is the rule, not the exception. Gorgey 2007^[2] documented obesity in roughly 60% of chronic spinal cord injury patients using SCI-adjusted BMI cutoffs; Ishimoto 2023^[4] found sarcopenic obesity in a substantial fraction of community-dwelling Japanese SCI patients, driven by the same mechanism.
• Energy expenditure is genuinely lower. Nevin 2024^[3] measured resting energy expenditure during inpatient rehabilitation and found standard predictive equations overestimate true REE in tetraplegia; fat-free-mass-based equations performed better but still required adjustment.
• The first GLP-1-in-SCI clinical paper exists, and there are no RCTs. Farkas 2026^[1] is a clinical-considerations review, not a trial. Fewer than ten peer-reviewed case reports describe GLP-1 use in SCI patients. The Farkas paper explicitly calls for prospective studies.
• Risk clusters are SCI-specific. Additive constipation on neurogenic bowel (Hultling 2020^[6]), additive hypotension on cardiovascular hyporeflexia, and pressure-injury risk from rapid loss of subcutaneous padding are the three concerns flagged across the rehabilitation literature.

Why SCI patients gain weight differently

Spinal cord injury triggers a cascade of changes that push energy balance toward positive. Below the level of injury, muscle mass declines rapidly during the first year, and resting energy expenditure falls roughly in proportion to the lost lean mass (Nevin 2024^[3]). The Harris-Benedict and Mifflin-St Jeor equations — both calibrated in able-bodied adults — overestimate caloric needs in tetraplegia by 10–20%, which routinely produces caloric overfeeding when uncorrected. Thermogenesis below the injury is impaired because the sympathetic nervous system below T6 cannot mount a normal thermogenic response, so cold-induced and diet-induced thermogenesis both shrink.

The downstream metabolic profile is well characterized. Nash 2020^[5] reviewed the cardiometabolic literature in SCI and reported elevated rates of type 2 diabetes, dyslipidemia with low HDL and high triglycerides, MASH (metabolic dysfunction-associated steatohepatitis), and accelerated atherosclerosis. The American Spinal Injury Association Impairment Scale grades injuries from A (complete) to E (normal); the higher the lesion and the more complete the injury, the larger the metabolic penalty. Tetraplegia carries more risk than paraplegia, complete more than incomplete.

What Farkas 2026 actually recommends

The 2026 Archives of Physical Medicine and Rehabilitation clinical-considerations paper (Farkas 2026^[1]) is the first dedicated guidance document for GLP-1 receptor agonists in spinal cord injury. The headline conclusions:

• GLP-1 therapy is potentially high-value because the obesity burden, cardiometabolic risk, and difficulty achieving sustained weight loss through conventional means are all amplified in SCI.
• No SCI-specific efficacy data exist. Published RCTs (STEP-1, SURMOUNT-1) excluded patients with significant neurological impairment; weight-loss estimates for SCI patients must extrapolate from able-bodied data.
• Slower dose escalation is reasonable. Standard 4-week step-ups may need to be lengthened to 6–8 weeks per step in SCI to allow bowel and autonomic adaptation.
• Bowel management must be reinforced before starting. Neurogenic-bowel regimens (digital stimulation, suppositories, oral laxatives, transanal irrigation per Hultling 2020^[6]) should be optimized and patients counseled that GLP-1 slowing of gastric emptying will further reduce stool frequency.
• Hypotension surveillance is required. Baseline blood pressure is chronically low in higher-level SCI; GLP-1-associated reductions in systolic and diastolic pressure may produce symptomatic orthostasis even though the absolute drop is small.

The neurogenic bowel problem

Constipation is the single most common GLP-1 adverse effect, affecting roughly a quarter of patients in the able-bodied registration trials. In spinal cord injury, the baseline rate of constipation is already 40–60% because neurogenic bowel disrupts colonic motility and impairs voluntary defecation (Hultling 2020^[6]). The additive effect is clinically meaningful and, in case reports, has produced ileus and pseudo-obstruction in SCI patients started on semaglutide without bowel-regimen reinforcement.

The practical protocol that the rehabilitation literature supports: continue or initiate scheduled bowel care every 24–48 hours, layer in osmotic laxatives (polyethylene glycol 17 g daily, often branded as MiraLAX) prophylactically rather than reactively, retain the sennosides or bisacodyl suppositories already in the regimen, and aggressively manage hydration. For patients on transanal irrigation, the schedule should not change with GLP-1 initiation, but the volume and contact time may need to be increased after the first month-on-dose.

Hypotension, autonomic dysreflexia, and the cardiovascular picture

Baseline blood pressure in higher-level spinal cord injury is characteristically low, often with systolic pressures in the 90–100 mmHg range and chronic orthostatic intolerance. GLP-1 receptor agonists produce small reductions in systolic and diastolic pressure (roughly 3–5 mmHg in able-bodied trial data) that are clinically welcome in hypertensive patients but can push SCI patients into symptomatic hypotension. The Farkas 2026 paper^[1] flags this as a surveillance domain: measure baseline supine and seated blood pressure, repeat at each dose step, and slow titration if symptomatic.

Autonomic dysreflexia — a hypertensive emergency triggered by noxious stimuli below the injury level — is the mirror-image concern (Eldahan 2018^[7]). Constipation and bladder distension are the two most common triggers; both are amplified by GLP-1-related delayed gastric emptying and reduced fluid intake. Patients with injuries at T6 or above must be counseled to maintain scheduled bowel care and clean intermittent catheterization to prevent dysreflexia episodes during titration.

Pressure injuries: weight loss reduces tissue padding

Spinal cord injury patients sit on the same bony prominences for hours every day, and the subcutaneous fat over the ischium, sacrum, and trochanter is the body’s primary defense against pressure ulceration. Rapid weight loss — particularly the 15–20% body-weight reductions seen on semaglutide 2.4 mg and tirzepatide 15 mg — removes that padding and can expose previously-protected skin to ischemic injury. The clinical-considerations paper recommends weekly skin checks during the first three months of GLP-1 therapy, more frequent cushion reassessment, and a formal seating clinic evaluation if total body-weight loss exceeds 10%.

Magnitude: 12-month weight loss in SCI patients with obesity

Semaglutide vs tirzepatide in SCI: no head-to-head

No randomized comparison of semaglutide and tirzepatide in spinal cord injury exists. From first principles, tirzepatide has a longer half-life (~5 days) and a smoother pharmacokinetic profile than semaglutide (~7 days but more variable absorption), which in theory may produce less peak-related nausea and less abrupt gastric-emptying slowing. Tirzepatide’s dual GIP/GLP-1 mechanism also produces greater absolute weight loss in able-bodied trials, which matters in a population with a higher obesity baseline. Counter-arguments: semaglutide has more cumulative post-marketing data and a slightly cheaper cash price after accounting for SCI-specific cost-share patterns. Either is reasonable; the Farkas 2026 paper does not recommend one over the other.

Bariatric surgery as the comparator

Sleeve gastrectomy in SCI patients is documented in at least two published case reports. Perreault 2016^[10]reported a chronic paraplegic patient who lost substantial weight and recovered ambulation function after sleeve gastrectomy; Corvatta 2024^[9] described a tetraplegic woman who used sleeve gastrectomy as a bridge to successful pregnancy. Peri-operative considerations include pressure-injury prevention during prolonged surgery, careful airway management in cervical injuries, and adapted nutrition protocols that account for reduced energy needs. For patients unwilling to commit to lifelong GLP-1 therapy, or who have contraindications, sleeve gastrectomy remains a feasible and documented option in this population.

The practical protocol

1. Pre-treatment optimization. Reinforce scheduled bowel care, document baseline supine and seated BP, photograph high-risk skin sites, and ensure the seating clinic has reviewed current cushion fit.
2. Slower dose escalation. Lengthen each step-up to 6–8 weeks rather than the standard 4 weeks. Start semaglutide 0.25 mg or tirzepatide 2.5 mg as usual.
3. Prophylactic bowel regimen. Add polyethylene glycol 17 g daily before the first dose. Keep stimulant agents (sennosides or bisacodyl) on hand. Track stool frequency in the patient diary.
4. Hydration target. 30–35 mL/kg/day, timed around catheterization schedule. Adequate hydration reduces both constipation and orthostatic symptoms.
5. Nutrition floor. Caloric floor of 1,200 kcal/day (not 1,000) given the already-reduced lean mass. Protein target 1.6–2.0 g/kg current body weight. See GLP-1 muscle loss prevention for the protein and resistance training evidence.
6. Resistance training adapted to capacity. Arm ergometry, resistance bands, and where available functional electrical stimulation cycling. Nightingale 2021^[8] reviewed exercise modalities for SCI obesity and reports the strongest evidence for high-intensity arm ergometry plus resistance work.
7. Body-composition tracking. Baseline DEXA and a repeat at end of titration (~week 36). The appendicular lean mass index drop should not exceed 15%.
8. Surveillance schedule. Weekly skin checks for 12 weeks, then monthly. BP at every dose step. Bowel diary review monthly. Stop or slow titration if any of these worsen.

Insurance, coverage, and provider routes

Medicaid coverage of GLP-1 receptor agonists for SCI patients with documented obesity is broadly more robust than for the general adult population because the cardiometabolic comorbidity rate is so high. Prior-authorization criteria typically require documentation of failed lifestyle intervention, prior nutrition consultation, and a covering comorbidity (T2D, MASH, sleep apnea, or BMI ≥ 35 with one weight-related comorbidity). The most efficient prescribing route is a coordinated triad of physiatry (physical medicine and rehabilitation), obesity medicine, and the patient’s SCI specialty clinic; each contributes a distinct piece of the PA packet. Cash pricing on Wegovy and Zepbound is no different in SCI than the general market.

Related research and tools

• GLP-1 muscle loss prevention — protein, resistance training, and DEXA tracking on a GLP-1
• GLP-1 in adults age 65 and older — sarcopenia screening parallels much of the SCI protocol
• The first 30 days on a GLP-1 — what to expect during initial titration

Important disclaimer. This article is educational and does not constitute medical advice. GLP-1 therapy in spinal cord injury should be initiated and monitored by a clinician with experience in both obesity medicine and SCI rehabilitation. Patients with autonomic dysreflexia history, recurrent pressure injuries, or symptomatic orthostatic hypotension at baseline require individualized risk-benefit assessment. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 6 months, or sooner if a prospective trial of GLP-1 therapy in spinal cord injury is published.